Abstract: An exemplary system, method, and computer-accessible medium for detection of functional disorder(s) or aging progression of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the functional disorder(s) or aging progression of the patient(s) based on the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map which can be a full dosage Gd enhanced cerebral blood volume map(s). The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), and/or (ii) a Gd-free MRI scan(s). Functional disorder(s) or age progression can include a neurodegenerative disease, a neuropsychiatric disease, a neurodevelopment disorder or aging.

Abstract: An exemplary system, method, and computer-accessible medium for detection of structural disorder(s) of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the structural disorder(s) of the patient(s) based on a GD contrast of the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map. The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), or (ii) a Gd-free MRI scan(s). The Gd contrast can be generated in the Gd enhanced map(s) using a T2-weighted MRI image of the portion(s). Structural disorder(s) can include Stroke, tumor, trauma, infection, Multiple sclerosis and/or other inflammatory disease.

Abstract: Methods for performing frequency and phase correction of magnetic resonance spectroscopy (MRS) data in quantifying one or more metabolites involved in the pathology of schizophrenia and related disorders.

Abstract: The present disclosure relates to methods and compositions for elevating and stabilizing retromer protein for treating and/or preventing neurodegenerative diseases and disorders including Alzheimer's disease and Parkinson's disease, where retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder. The methods include the use of agents to elevate and stabilize specific retromer depending upon the neurodegenerative disease or disorder being treated. The method can also include the use of one or more biomarkers to detect and/or identify whether retromer dysfunction and/or endosomal trafficking dysfunction is involved and/or implicated in the disease or disorder.

Abstract: The present disclosure relates to methods and compositions for elevating and stabilizing retromer for treating and/or preventing Alzheimer's disease and other neurodegenerative diseases or disorders. Additionally, the disclosure relates to gene therapy combined with a pharmacological retromer chaperone therapy for treating and/or preventing Alzheimer's disease (AD), and other neurodegenerative diseases or disorders such as Parkinson's Disease (PD), amyotrophic lateral sclerosis (ALS), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathies (TSEs or prion disease), multiple system atrophy (MSA), as well as tauopathies such as progressive supranuclear palsy (PSP), frontotemporal lobar dementia linked to chromosome 17q21-22 and its subtypes (FTLD-17/FTLD-Tau), and chronic traumatic encephalopathy (CTE).

Abstract: The present disclosure relates to methods and compositions for elevating and stabilizing retromer for treating and/or preventing Alzheimer's disease and other neurodegenerative disorders. Additionally, the disclosure relates to adenoviral based therapy for treating Alzheimer's disease (AD), and other neurodegenerative conditions such as Parkinson's Disease (PD), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathies (TSEs or prion disease), multiple system atrophy (MSA), Down's syndrome, and hereditary spastic paraplegia, as well as tauopathies such as progressive supranuclear palsy (PSP), frontotemporal lobar dementia linked to chromosome 17q21-22 and its subtypes (FTLD-17/FTLD-Tau), Lewy Body Disease (LBD), amyotrophic lateral sclerosis (ALS), frontal-temporal degeneration (FTD), ALS-FTD, and chronic traumatic encephalopathy (CTE).

Abstract: A method for classifying neurological disease status is described. The method includes acquiring, by a data preprocessor logic, patient image data. The method further includes generating, by a trained artificial neural network (ANN), a classification output based, at least in part, on the patient image data. The classification output corresponds to a neurological disease status of the patient. The trained ANN is trained based, at least in part, on longitudinal source data.

Abstract: An exemplary system, method, and computer-accessible medium for detection of functional disorder(s) or aging progression of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the functional disorder(s) or aging progression of the patient(s) based on the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map which can be a full dosage Gd enhanced cerebral blood volume map(s). The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), and/or (ii) a Gd-free MRI scan(s). Functional disorder(s) or age progression can include a neurodegenerative disease, a neuropsychiatric disease, a neurodevelopment disorder or aging.

Abstract: An exemplary system, method, and computer-accessible medium for detection of structural disorder(s) of patient(s) can be provided which can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), generating gadolinium (“Gd”) enhanced map(s) based on the MRI information using a machine learning procedure(s), and detecting the structural disorder(s) of the patient(s) based on a GD contrast of the Gd enhanced map(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map. The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), or (ii) a Gd-free MRI scan(s). The Gd contrast can be generated in the Gd enhanced map(s) using a T2-weighted MRI image of the portion(s). Structural disorder(s) can include Stroke, tumor, trauma, infection, Multiple sclerosis and/or other inflammatory disease.

Abstract: An exemplary system, method, and computer-accessible medium for generating a gadolinium (“Gd”) enhanced map(s) of a portion(s) of a patient(s), can include, for example, receiving magnetic resonance imaging (MRI) information of the portion(s), and generating the Gd enhanced map(s) based on the MRI information using a machine learning procedure(s). The Gd enhanced map(s) can be a full dosage Gd enhanced map. The full dosage Gd enhanced map(s) can be a full dosage Gd enhanced cerebral blood volume map(s). The machine learning procedure can be a convolutional neural network. The MRI information can include (i) a low-dosage Gd MRI scan(s), or (ii) a Gd-free MRI scan(s). A Gd contrast can be generated in the Gd enhanced map(s) using a T2-weighted MRI image of the portion(s).

Abstract: A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image. The second image and the first image are aligned within an imaging space. The first image is post-contrast. The second image is pre-contrast. The technology enables determining, via the computer, a voxel intensity mean value of a segment of the vessel in the third image. The technology enables obtaining, via the computer, a fourth image from a division of the third image by the voxel intensity mean value. The technology enables applying, via the computer, a filter onto the fourth image. The technology enables generating, via the computer, a filter mask based on the fourth image.

Abstract: A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image. The second image and the first image are aligned within an imaging space. The first image is post-contrast. The second image is pre-contrast. The technology enables determining, via the computer, a voxel intensity mean value of a segment of the vessel in the third image. The technology enables obtaining, via the computer, a fourth image from a division of the third image by the voxel intensity mean value. The technology enables applying, via the computer, a filter onto the fourth image. The technology enables generating, via the computer, a filter mask based on the fourth image.

Abstract: A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image. The second image and the first image are aligned on an imaging space. The first image is post-contrast. The second image is pre-contrast. The technology enables determining, via the computer, a voxel intensity mean value of a segment of the vessel in the third image. The technology enables obtaining, via the computer, a fourth image from a division of the third image by the voxel intensity mean value. The technology enables applying, via the computer, a filter onto the fourth image. The technology enables generating, via the computer, a filter mask based on the fourth image.

Abstract: Methods and systems for measuring brain function of a person are disclosed. In some embodiments, the methods include the following: providing a database including digital image files that define intersecting sinusoidal functions; conducting matching trials including displaying a first image selected from the digital image files for a first amount of time, displaying no images for a second amount of time, and displaying both the first image and a second image, prompting the person to identify the first image, recording whether the person correctly identified the first image, and recording an amount of time to complete the matching trial; and conducting recognition trials including displaying an image selected from the digital image files, prompting the person to identify whether the image was displayed in the matching trials, recording whether the person correctly identified whether the image was displayed, and recording an amount of time to complete the recognition trial.

Abstract: A technology which enables identifying, via a computer, a vessel in a third image. The third image is obtained from a subtraction of a second image from a first image. The second image and the first image are aligned on an imaging space. The first image is post-contrast. The second image is pre-contrast. The technology enables determining, via the computer, a voxel intensity mean value of a segment of the vessel in the third image. The technology enables obtaining, via the computer, a fourth image from a division of the third image by the voxel intensity mean value. The technology enables applying, via the computer, a filter onto the fourth image. The technology enables generating, via the computer, a filter mask based on the fourth image.

Abstract: Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject.

Abstract: The present invention provides pharmaceutical compositions and related methods for stabilizing retromer in cells.

Abstract: Described is a transgenic mouse with two transgenes, each of which transgene comprises a DNA sequence encoding a dominant negative form of RbAp48 protein, wherein the expression of the dominant negative form of RbAp48 is spatially restricted to the forebrain by a CaM Kinase IIa promoter and wherein the expression of the dominant negative form of RbAp48 is controlled by tetracycline-controlled transcriptional activation. Also provided are methods for evaluating in the transgenic mouse the potential therapeutic effect of an agent for slowing, inhibiting or preventing age-related memory decline in a mammalian subject.

Abstract: The present invention provides pharmaceutical compositions and related methods for stabilizing retromer in cells.

Abstract: Disclosed herein are methods for treating a disease involving ?-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Also disclosed are methods for reducing the amount of ?-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce ?-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce ?-synucleic aggregation; or (3) a compound which inhibits ?-synucleic aggregation in an amount effective to reduce ?-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.